Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

ClinicalTrials.gov ID: NCT06619990

Public ClinicalTrials.gov record NCT06619990. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.

Study identification

NCT ID: NCT06619990
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Xencor, Inc.; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

Ulcerative Colitis (UC)

Interventions

Placebo Drug
XmAb942 Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 9, 2024
Primary completion: Mar 31, 2028
Completion: Dec 31, 2028
Last update posted: May 5, 2026

2024 – 2029

United States locations

U.S. sites: 19
U.S. states: 6
U.S. cities: 18

Facility	City	State	ZIP	Site status
Xencor Investigative Site	Scottsdale	Arizona	85255	Recruiting
Xencor Investigative Site	Bradenton	Florida	34209	Recruiting
Xencor Investigative Site	Brandon	Florida	33511	Recruiting
Xencor Investigative Site	Jacksonville	Florida	32258	Recruiting
Xencor Investigative Site	Kissimmee	Florida	34741	Recruiting
Xencor Investigative Site	Margate	Florida	33063	Recruiting
Xencor Investigative Site	Palmetto Bay	Florida	33176	Recruiting
Xencor Investigative Site	Tampa	Florida	33613	Recruiting
Xencor Investigative Site	Louisville	Kentucky	40218	Recruiting
Xencor Investigative Site	Raleigh	North Carolina	27612	Recruiting
Xencor Investigative Site	Beavercreek	Ohio	45440	Recruiting
Xencor Investigative Site	Denton	Texas	76201	Recruiting
Xencor Investigative Site	Georgetown	Texas	78628	Recruiting
Xencor Investigative Site	Houston	Texas	77024	Recruiting
Xencor Investigative Site	Houston	Texas	77090	Recruiting
Xencor Investigative Site	Kingwood	Texas	77339	Recruiting
Xencor Investigative Site	Lubbock	Texas	79424	Recruiting
Xencor Investigative Site	San Antonio	Texas	78229	Recruiting
Xencor Investigative Site	Tyler	Texas	75701	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06619990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06619990 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →